Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat tosylate monotherapy for relapsed/refractory peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma
2023-507381-13-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of valemetostat in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia-lymphoma (ATLL) (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Overall response rate and Safety. Planned start Feb 2024; status: authorised.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on 2023-507381-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507381-13-00.